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Background: Bleeding from a damaged blood vessel is stopped by the
formation of a platelet plug. The multimeric plasma glycoprotein, von Willebrand
factor (vWF), plays an essential role in this process by anchoring blood
platelets to the damaged vessel wall under conditions of high shear stress. This
factor mediates platelet adhesion by binding both to collagen of the damaged
blood vessel and to glycoprotein Ib on the platelet membrane. The A3 domain
of vWF allows it to bind to collagen types I and III present in the perivascular
connective tissue of the damaged vessel wall. To gain insight into the
mechanism of collagen binding by vWF, we have determined the crystal
structure of the human vWF A3 domain.
Results:  The crystal structure of the 20 kDa A3 domain of human vWF
(residues 920–1111), determined by the method of multiwavelength anomalous
dispersion at 1.8 Å resolution, exhibits a common dinucleotide-binding fold. The
putative collagen-binding site of the A3 domain is rather smooth and shows a
markedly high concentration of negatively charged residues. This region
encompasses a potential metal-binding site containing the motif DXSXS, which
is required for ligand interaction in the homologous I-type domains of integrins
CR3 and LFA-1. Although vWF A3 has considerable sequence and structural
similarity with CR3 and LFA-1 in this region, one loop of A3 adopts a
conformation which is incompatible with ion binding.
Conclusions: The structure of the A3 domain suggests that adhesion to
collagen is primarily achieved through interactions between negatively charged
residues on A3 and positively charged residues on collagen. The absence of a
pronounced binding groove precludes a large van der Waals surface interaction
between A3 and collagen and is consistent with the low affinity for collagen of a
single A3 domain and the requirement for multimeric vWF for tight association
with collagen. The absence of bound metal ions upon soaking the crystal in
MgCl2 and vWF A3’s conformational incompatibility for metal binding is
consistent with the absence of a functional role for metal ion binding in A3,
which contrasts the metal ion activation required for ligand binding by the
homologous integrin I-type domains.
Introduction
Bleeding from a damaged blood vessel is stopped, a pro-
cess known as haemostasis, by the formation of a platelet
plug. Platelet plug formation starts with adhesion of blood
platelets to perivascular connective tissue that is exposed
at the site of vascular damage. Adhered platelets become
activated, enabling them to incorporate additional non-
activated platelets into the growing plug. The resulting
platelet plug is further stabilized by a fibrin network
formed by the thrombin-catalyzed conversion of fibrino-
gen to fibrin [1]. An essential role in the initial adhesion
of platelets to damaged blood vessels is played by von
Willebrand Factor (vWF) [2]. This factor mediates plate-
let adhesion by binding both to the damaged vessel wall,
primarily through collagen, and to glycoprotein Ib (GpIb)
located on the platelet membrane. The binding of vWF
to perivascular connective tissue involves collagen types I
and III, whereas collagen type VI has been implicated in
the binding to the subendothelial matrix [3]. vWF is a
multimeric glycoprotein composed of upto 80 monomers
linked by disulfide bonds. The larger multimers of vWF
are most active in haemostasis [4]. Electron microscopy
[5] and atomic force microscopy [6] show that vWF multi-
mers have a compact “ball of yarn” conformation, which
is unwound into an extended conformation under the in-
fluence of shear stress [6]. Such an extended vWF multi-
mer measures up to a few micrometers in length, a similar
size to the diameter of a blood platelet, and potentially
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contains a large number of exposed interaction sites to
mediate adhesion of platelets to the damaged vessel wall.
A vWF monomer consists of 2,050 amino acid residues
and contains multiple copies of four types of domains
called A, B, C and D-type domains [7,8]. Several func-
tions of vWF have been mapped to specific domains: the
D ¢ and D3 domains bind to coagulation factor VIII and
protect it from degradation [9]; the C1 domain binds inte-
grin a IIb b 3 through its Arg–Gly–Asp (RGD) sequence
motif [10,11]; and the A-type domains contain the
binding sites for collagen and GpIb. A cassette of three A-
type domains is present in vWF. The A1 domain
(residues 509–695) contains the GpIb-binding site
[12–14], a heparin-binding site [15], a sulfatide-binding
site [16] and a minor binding site for collagen types I and
III [13,17,18]. The collagen-binding site in the A1
domain does not sustain platelet adhesion under flow
conditions by itself [19]. The A2 domain (residues
730–907) does not have a known adhesive function, and
deletion of this domain from vWF does not significantly
affect either collagen or GpIb binding [20]. A2 contains a
proteolytic cleavage site, however, which may play a role
in the physiological regulation of the multimeric size of
vWF [21]. The main collagen type I and III binding site
of vWF resides on the A3 domain (residues 923–1109)
[19,22]. Very little residual collagen-binding activity was
observed for a deletion mutant of vWF lacking the A3
domain that was expressed in baby hamster kidney cells
and displayed a normal distribution of multimer size [19].
A bacterial construct of the A3 domain consisting of
residues 908–1111 binds collagen, albeit with only micro-
molar affinity [22]. This low affinity of the isolated A3
domain for collagen most likely reflects the importance of
the multimeric size of vWF for collagen binding, which
agrees with the observation that long multimers of vWF
bind most efficiently to collagen [23].
Since they were first discovered, the vWF A-type domains
have become the prototype of a large number of homolo-
gous adhesion domains that have subsequently been found
in a wide range of proteins, including integrins and several
collagen types [24]. The crystal structures of two A-type
domains from the integrins CR3 (also known as a M, CD11b
or mac-1) and LFA-1 (a L or CD11a), also called inserted or
I-type domains, have been determined [25,26]. Both inte-
grin I-type domains possess a metal-binding site, with high
affinities for Mg2+ and Mn2+, which has been implicated in
integrin activation and ligand binding [27]. The metal-
binding site is formed by an aspartate and two serines
present in a DXSXS sequence, and by a threonine and a
second aspartate, which are conserved in many A-type
domains. Lee et al. [25] suggest that the observed structural
motif plays a functional role in binding of protein ligands
and represents a general metal ion-dependent adhesion
site, also coined MIDAS site. The residues involved in
metal chelation appear to be conserved in the sequence of
A3 [25]; however, a role for metal ions in the association of
vWF to collagen has not been established [28,29].
To gain insight into the mechanism of collagen binding
by von Willebrand factor, we have overexpressed the A3
domain from human vWF (residues 920–1111) and have
determined its crystal structure at high resolution. The
crystal structure reveals a dinucleotide-binding fold
similar to that observed for the crystal structures of the
I-type domains of integrins CR3 and LFA-1. In contrast
to the I domains and despite conservation of metal
chelating residues, no metal ion binding site appears to
be present in the vWF-A3 domain. A putative collagen-
binding site is identified. This binding site is relatively
smooth and predominantly negatively charged, suggest-
ing a primary role for interaction with positively charged
residues on collagen.
Results
We produced and crystallized a recombinant A3 domain
from human vWF consisting of residues 920–1111 and
solved its structure using the technique of multiwave-
length anomalous dispersion with a selenomethionine (Se-
Met) derivative that crystallized in space group P212121
(Tables 1 and 2). The structure of the A3 domain has
been refined with good model geometry to an R factor of
17.4% (Rfree = 24.0%) using 1.8–8.0 Å resolution data from
a native crystal with space group P21 (Table 3). Two
vWF-A3 molecules (referred to as A and B) are present in
the asymmetric unit of the native P21 crystal. The two
molecules are related by a non-crystallographic twofold
screw axis that runs nearly perpendicular to the crystallo-
graphic twofold screw axis. The four molecules contained
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Table 1
Data collection statistics.
Dataset identifier Native Inflection Edge Remote
Space group P21 P212121 P212121 P212121
Wavelength (Å) 0.98 0.9792 0.9790 0.90
Resolution (Å) 20–1.12 20–2.3 20–2.3 20–2.3
Completeness (%) 99.9 96.0 96.8 97.9
Redundancy 6.2 3.2 2.6 3.4
Rsym* (%) all data 5.4 5.3 4.0 4.4
high-resolution data† 30.9‡ 9.0 8.2 8.7
<I/ s I> all data 30.9 21.4 23.2 27.7
high-resolution data† 3.6 10.5 10.7 12.4
*Rsym = S (| I– < I > |) / S (I). †Resolution shell 1.13–1.12 Å for native
and 2.37–2.20 Å for MAD data. ‡Rsym is 5.9% in a resolution shell from
1.8 to 1.9 Å, which corresponds to the highest resolution data used in
refinement. 
within the unit cell almost, but not quite, obey P212121
space group symmetry as observed for crystals grown
from Se-Met A3.
Overall structure
The vWF A3 domain adopts a so called dinucleotide-
binding fold (Figure 1). It consists of a central b sheet with
six strands (labelled b 1–b 6) that is surrounded by seven a
helices (labelled a 1–a 7). The b strands are parallel, except
for strand b 3 which is located at an edge of the sheet. A
disulfide bridge between residues Cys923 and Cys1109
connects the N- and C-terminal regions and denotes the
domain boundaries. Secondary structural elements and
amino acid sequence of the A3 domain are depicted in
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Table 2
MAD data and phasing statistics.
Dataset identifier Inflection Edge Remote
c
2*
inflection 1.6 2.3 7.7
edge 2.3 3.7 2.9
remote 7.7 2.9 3.7
R value† (%)
inflection 2.9 2.7 4.1
edge 2.7 4.6 2.7
remote 4.1 2.7 3.5
Phasing power‡
isomorphous 2.2 1.5 §
anomalous 0.6 1.1 1.1
*c 2 = S (( I – <I> )2 / (s I2 · N / (N-1) )). †R = S (|I – <I> |) / S (I). c 2 and
R values are calculated between Bijvoet pairs within one data set or
between merged Bijvoet pairs for different data sets. ‡Phasing
power = <FH /e >, where e is the lack of closure. §The remote data set
was used as native data in the calculations.
Table 3
Final refinement and stereochemical statistics for native P21
crystal form.
R value (%)
8.0–1.8 Å 17.4
1.9–1.8 Å 22.2
Rfree* (%)
8.0–1.8 Å 24.0
1.9–1.8 Å 28.0
Average B value (Å2)
molecule A 11.1
molecule B 11.8
solvent (350 waters) 22.6
Rms deviations 
bonds (Å) 0.009
angles (° ) 1.44
B values bonded atoms (Å2) 1.8
*A subset consisting of 7.5% of the data was used for cross-validation.
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Structure of the vWF A3 domain. (a) Ribbon drawing with the cysteine
bridge that links the N- and C-terminal parts of the molecule shown in
ball-and-stick representation. Loop segments that contribute residues
to the potential ion-binding site are coloured green, a helices are blue
and b strands red. (b) Stereo picture of the C a trace of vWF A3. The
orientation has been rotated approximately 90° around a vertical axis
relative to the orientation shown in (a). Figure was drawn using
MOLSCRIPT [53].
Figure 2. The two molecules present in the asymmetric
unit are very similar and have a root mean square (rms)
coordinate difference of 0.38 Å for Ca atoms after superpo-
sitioning. The differences between A and B that are larger
than 0.8 Å occur in loop a 5b 6 and loops a 1b 2 and b 3a 2,
which are located closely together. The difference in loop
a 5b 6 is caused by very poor electron density for residues
1079–1083 in molecule B, making interpretation ambigu-
ous. The electron density for loops a 1b 2 and b 3a 2, on the
other hand, is excellent. The conformational difference in
these loops appears to be triggered by a difference in
crystal contacts for residue Asn983. The electron density of
the N and C termini in molecule A is not as clearly defined
as in molecule B. The model for molecule B includes
residues 922–1110, whereas the model for molecule A only
extends from residue 925 to 1107 and misses the disulfide
bonded cysteines.
The overall structure of the vWF A3 domain was com-
pared to the structures of the CR3 and LFA-1 I-domains.
The amino acid sequences of the CR3 and LFA-1 I
domains are more closely related to each other (33% se-
quence identity) than either of them are related to the
vWF A3 domain (CR3-A3 21% identity, LFA1-A3 20%
identity). Correspondingly, the rms coordinate differences
after superpositioning are 1.1 Å for 169 matched Ca atoms
of CR3 (PDB entry code 1JLM) and LFA-1 (PDB entry
code 1ZON), 1.4 Å for 166 Ca atoms of CR3 and vWF A3
and 1.4 Å for 160 Ca atoms of LFA-1 and vWF A3.
Figure 2 shows the structure-based sequence alignment of
the vWF A3 domain with the CR3 and LFA-1 I domains.
Most, but not all, of the secondary structure elements are
conserved in all three molecules. In CR3 and LFA-1, helix
a 2 is shorter by four residues and is preceded by an addi-
tional short helix that is absent in A3. In A3, helices a 6
and a 7 are separated by a 90 ° bend, whereas one uninter-
rupted helix is present in LFA-1, and CR3. In different
crystal forms of CR3 and LFA-1, considerable, variation is
observed in the position of the C-terminal helix [30,31].
This variation has been attributed to crystal packing
effects and to differences in bound metal ions. In the vWF
A3 domain, the C-terminal region (helices a 6 and a 7) is
well-packed against the main body of the domain; it most
resembles CR3 in complex with manganese (PDB code
1JLM) and LFA-1 without a metal ion bound (PDB code
1ZON). The C-terminal helices in vWF A3 may be more
restrained due to the presence of a disulfide bond
between Cys923 and Cys1109. As mentioned above, the
disulfide bond itself is ill-defined in the electron density
of molecule A, however.
Analysis of conformation of MIDAS site
In the crystal structure of the vWF A3 domain, we do not
observe a bound metal ion near the residues corresponding
to the MIDAS site in CR3 and LFA-1, not even in the pres-
ence of 10 mM MgCl2 (data not shown). Residues corre-
sponding to metal-chelating residues in CR3 and LFA-1 are
indicated in Figure 2. Difference density that could not be
attributed to protein atoms was satisfactorily modeled as
water molecules. Analysis of the coordination sphere of
these water molecules with the program WASP [32] shows
that the observed coordination would not be favourable for
metal ions, making it unlikely that a metal ion has been
misidentified as a water molecule.
The conformation of the DXSXS motif (Asp934, Ser936
and Ser938 — three potential metal-coordinating residues
in loop b 1 a 1) in the vWF A3 domain is nearly identical to
that of the analogous regions in CR3 and LFA-1 (see
Figure 3). Ser1005 in A3 (loop a 2a 3) is equivalent to and
its hydroxyl group points in the same direction as the coor-
dinating threonine residues 209 and 206 present in CR3
and LFA-1, respectively. The fifth coordinating residue
has been predicted to be Asp1039 (loop b 4a 4) [30]. In the
crystal structure of vWF A3, however, Thr1038 is ob-
served at this position, thus sequence alignment based on
the structure (Figure 2) suggests a shift of one residue in
this region. The position following that occupied by the
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Figure 2
Secondary structure assignment of vWF A3
and structure-based sequence alignment of
vWF A3 with the I domains from CR3 and
LFA-1. Residue numbering and secondary
structure elements refer to the vWF A3
domain. Residues in a helices and b strands
are colored blue and red, respectively.
Residues of A3 in italics are not visible in the
electron-density map, this includes the vector-
derived GSHM sequence at the N terminus.
Lower case letters in the CR3 and LFA-1
sequences denote residues whose Ca atoms
cannot be superimposed within 2.5 Å of a
residue in vWF A3. Residues in CR3 and
LFA-1 involved in metal binding and the
corresponding residues in vWF A3 are shown
in bold. Secondary structure assignments for
CR3 and LFA-1 were taken from [30] and
[26], respectively.
                   920       930       940       950       960       970       980
                              b1                                      a1                                               b2                  b3
vWF A3          GSHMAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNV
CR3 I (132–188)           DSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQLkkS--KTLFSLMQYSEEFRIHFTFKE
LFA1 I(128–185)          GNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLsnt--SYQFAAVQFSTSYKTEFDFSD
 
                    990      1000      1010      1020      1030      1040
                      a2                                               a3                                               b4                                     a4
vWF A3          VPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILVTDVSVD---SVDAAA
CR3 I (189–256) fqnnpnpRSLVKPITQLLGRTHTATGIRKVVRelfnItNGARKNAFKILVVITDGEKFgdplGYeDVI
LFA1 I(186–248) yvkrkDpDALLkHVKHMLLLTNTFGAINYVATevfreeLGARPDATKVLIIITDGEATD---Sgn--i
                1050    1060          1070      1080      1090      1100      1110
                                   b5                                    a5                               b6                   a6                   a7
vWF A3          DAARSNRVTVFPIGIGDRY----DAAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSG
CR3 I (257–318) PEADREGVIRYVIGVGDAfrsekSRQELNTIAskpprdHVFQVNNFEALktIQ---nqLREKIfa
LFA1 I(249–308) DAAK--DIIRYIIGIGKHfqtkesQETLHKFAskpasEFVKILDTFEKLkDLF---tELQKKIyv
metal ion-binding residues, Asp242 and Asp239 in CR3
and LFA-1, respectively, is occupied by a glycine in these
two I-type domains. In A3, however, this position is occu-
pied by Asp1039. The carboxylate moiety of Asp1039
points to the solvent, away from the putative metal-bind-
ing site (Figure 3a). Its Cb atom comes within 3.5 Å of the
putative ion position (deduced from superpositioning of
CR3 and LFA-1 onto A3) and effectively blocks metal
binding in this configuration.
Surface properties
The A3 domain can be thought of as a rectangular box
with six faces. With reference to the orientation depicted
in Figure 1a, the left and right faces of this box are formed
by surface-exposed residues in the a helices. The front
and back face in this view are formed by the outer strands
of the b sheet as well as by residues of the neighbouring
‘outer’ a helices. The top and bottom are formed by loops
connecting elements of secondary structure. The N and C
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Figure 3
Comparison of vWF A3 with MIDAS sites of
the I domains of CR3 and LFA-1. Stereo
pictures of the corresponding regions in A3
(a), CR3 with bound Mg2+ (b) and LFA-1 with
bound Mg2+ (c). Residues and water
molecules involved in metal chelation in CR3
and LFA-1 and corresponding residues in
vWF A3 are shown in ball-and-stick
representation. The Mg2+ ions are shown in
magenta and a coordinating Cl– ion in LFA-1
in green. The backbone trace of a symmetry-
related molecule in CR3, which provides a
metal coordinating glutamate residue, is
shown in brown. Figure was drawn using
MOLSCRIPT [53].
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termini of the domain are both located at the bottom face
and are part of the linker regions connecting the neigh-
bouring domains to A3 (i.e. domains A2 and D4 in com-
plete vWF). The region corresponding to the active sites
or ligand-binding sites in all proteins with a dinucleotide-
binding fold is located at the top face [33].
The solvent accessible surface of the A3 domain is pre-
dominantly hydrophilic with the exception of one region
located at the bottom and back face of the molecule,
where residues from loop b 3 a 2, helix a 2 and flanking loop
a 1 b 2 form an extended but not fully continuous hydro-
phobic region. Residues contributing to this hydrophobic
region are Val984, Val985, Pro986, Leu994 and Val997.
The proximity of this hydrophobic region to the N- and C-
terminal residues is consistent with a potential hydropho-
bic interdomain interaction site. Few exposed hydropho-
bic residues are observed at the left and right a -helical
faces and the front face. The top face of the molecule,
containing the putative ligand-interaction surface, is also
primarily hydrophilic (see Figure 4a). Two small hydro-
phobic patches are observed on this face: one due to
Pro940, and the other due to Pro1004, Val1040 and Val1042.
The latter patch can be regarded as a small hydrophobic
ridge that is located close to the site corresponding to the
metal-binding sites in CR3 and LFA-1. 
The distribution of charged residues over the surface 
of the molecule is markedly asymmetric. The positively
charged residues (seven lysines and nine arginines) are
more or less randomly distributed over the whole surface,
whereas a significant proportion of the negatively charged
residues (nine out of fifteen aspartates and two out of five
glutamates) is located on the top side of the molecule,
either in loops or in the last turn of a helices. This asym-
metric charge distribution yields a large dipole moment
(491 Debye as calculated by the program GRASP [34])
which is approximately oriented along strand b 1. Corre-
spondingly, the top face of the molecule contains a large
negatively charged patch (see Figure 4b) and, further-
more, contains two positively charged residues: Arg1000
and Arg1067. The relatively large negatively charged area
encompasses the region that corresponds to the MIDAS
site in CR3 and LFA-1.
Discussion
Absence of cation binding
Although binding of vWF to collagen does not appear to
be metal ion-dependent [28,29], conservation of residues
that are involved in metal chelation in integrin I domains
[25] suggests that the A3 domain may possess a metal-
binding site. It is possible that ion binding plays a struc-
tural role, if not an undetected functional role. In the A3
crystal structure, we do not observe a bound metal ion,
even in the presence of 10 mM MgCl2. Comparison of A3
with the MIDAS sites in CR3 and LFA-1 (see Figure 3)
revealed considerable structural similarity for the residues
in the DXSXS motif; however, significant differences
were observed for the remainder of the hypothetical A3
MIDAS site. In A3, Thr1038 occupies the position of
Asp242 and Asp239, which chelate the bound ion directly
and indirectly via a bridging water molecule in CR3 and
LFA-1, respectively. The replacement of a negatively
charged carboxylate group with a hydroxyl group dimin-
ishes the cation-binding potential of A3. Furthermore, the
placement of Asp1039 instead of a glycine, found in the
equivalent position that follows Asp242 and Asp239 in the
structures of CR3 and LFA-1, causes steric hindrance and
prevents metal-ion binding of vWF A3 in this configura-
tion. Ion binding to A3 would therefore require structural
rearrangements. We observe no crystal contacts in the
immediate vicinity of the potential ion binding site in A3
and would, therefore, have expected to observe ion binding
after soaking crystals in 10 mM MgCl2. In the structures of
CR3 and LFA-1, structural variations are observed among
different crystal structures with and without Mg2+ or Mn2+
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Figure 4
Surface properties of the top face of the A3 domain. (a) Solvent-
accessible surface with hydrophilic and hydrophobic regions indicated
in white and green, respectively. (b) Molecular surface with positive
and negative electrostatic potential colored blue and red, respectively.
The circle indicates the position of the potential metal-binding site. The
figure was produced using the program GRASP [34].
bound [30,31]. Lee et al. [30] assigned a functional role to
the observed flexibility and proposed metal binding to be
the molecular basis of the activation mechanism in I-type
domains. In contrast, the currently available data on vWF
A3 does not reveal a role for metal ions and activation for
collagen binding appears not required. 
A putative collagen-interaction surface
The crystal structure of the vWF A3 domain does not
clearly demonstrate how A3 interacts with collagen. The
A3 domain does not have a large groove that easily identi-
fies the collagen-binding site; however, all proteins with a
dinucleotide-binding fold known to date have their active
site or binding site located at the C-terminal side of the b
sheet [33]. Residues located at this side of the b sheet
have been implicated in ligand binding to integrin I-type
domains [35–38]; this is of particular relevance, because,
within the diverse family of proteins with a dinucleotide-
binding fold, the integrin I domains are most related in
sequence and structure to the vWF-A3 domain. Involve-
ment of this side of the A3 domain in collagen binding is
further supported by epitope mapping of a vWF–inhibit-
ing antibody. Van Genderen et al. [39] described a patient
with impaired vWF activity caused by the presence of an
IgM antibody that inhibits the interaction between vWF
and collagen. Analysis of this patients serum with a
PEPSCAN of the A3 domain (data not shown) indicated
that the epitope of this antibody includes a peptide com-
prising residues 1036–1047 (loop b 4 a 4) located on the
C-terminal side of the b sheet. We, therefore, pose that
this side of the A3 domain contains the collagen-inter-
action site. This face of the molecule is relatively smooth
and contains a large negatively charged region, two iso-
lated positive charges and a small hydrophobic patch. The
excess of negative charge suggests a possible electrostatic
interaction with positively charged residues on collagen;
this is in accordance with the observation of Fitzsimmons
et al. [40] that chemical modification of arginines on colla-
gen reduces vWF binding.
The putative interaction surface of A3 is distinctly differ-
ent from the collagen-binding sites described for the
structures of the fibronectin type-2 module 1F2 [41] and
several collagenases ([42,43] and references therein). 1F2
binds preferentially to denatured collagen (gelatin) and
the crystal structure reveals an extensive hydrophobic sur-
face with a hydrophobic pocket. In collagenase, two dis-
tinct domains are involved in collagen interaction. One of
these, the catalytic domain has a groove that can accom-
modate a single peptide strand of a partly unwound triple
helix. The second domain is required for unwinding; both
the mechanism of unwinding and the mode of interaction
between collagen and the second domain are not known
in detail. Binding of vWF to collagen requires the pres-
ence of a collagen triple helix, because vWF does not bind
to gelatin [29,44,45]. Moreover, vWF binds with highest
affinity to polymeric forms of collagen, such as native col-
lagen fibrils, single-length spacing aggregates and ran-
domly cross-linked triple helices [44,45]. High affinity for
different polymeric forms, including randomly cross-linked
triple helices, indicates that a specific arrangement of
triple helices within a polymer is not required for tight
binding. Therefore, the vWF-binding site is primarily,
possibly exclusively, located on a single triple helix. More-
over, studies using CNBr-fragments of collagen types I
and III [40] show that along a single triple helix there are
multiple binding sites for vWF. Thus, tight binding most
likely results from interactions of multiple, and indepen-
dent, binding sites formed by individual helices in a colla-
gen aggregate with multiple A3 domains present in the
vWF multimer.
The size of the vWF A3 domain limits the number of
residues of an extended collagen triple helix that can
interact with the putative collagen-interaction surface. A
collagen triple helix has a diameter of ~ 15 Å and a rise of
~ 9 Å for a tri-peptide repeat (Gly–X–Y). The size of the
vWF A3 putative interaction surface (maximal length of
~ 25 Å) allows interaction with at most three consecutive
tri-peptide units (i.e. nine residues with an approximate
length of 27 Å). The absence of a binding groove in the
interaction surface of A3 most likely implies binding to
two polypeptide chains of a collagen triple helix. The
structural data, the low affinity of the isolated A3 domain
for collagen (Kd ~ 2 m M) [22] and the presence of multiple
binding sites along the collagen triple helix [40] are consis-
tent with a limited van der Waals contact area, resulting
from association of one face of a collagen triple-helical rod
with the relatively smooth interaction surface of A3 and a
limited number of residues involved in specific interac-
tions. A small region and a limited sequence pattern of
collagen is therefore recognized by vWF A3.
Biological implications
Bleeding from a damaged blood vessel is stopped (haemo-
stasis) by the formation of a platelet plug. A multimeric
glycoprotein, von Willebrand factor (vWF) is essential
for normal haemostasis, as is evident from the bleeding
disorder which occurs when vWF is either absent or
functionally abnormal. Binding of multimeric vWF to
fibrillar collagen type I and/or III is a necessary pre-
requisite for it to function as a bridge between the con-
nective tissue of the vessel wall and its receptor on the
platelet membrane, glycoprotein Ib (GPIb). Defects in
function of vWF in interacting with GPIb have been
described in type 2A and 2M von Willebrands disease.
No report has thus far appeared on a vWF molecule
that is deficient in binding to collagen type I and III as
cause of a bleeding disorder; however, specific inhibi-
tion of vWF collagen adhesion was recently described
for a patient with an IgM antibody to vWF [39]. The
importance of vWF binding to collagen for normal
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haemostasis is further underlined by the existence of
two proteins isolated from the saliva of two leeches,
which specifically inhibit vWF binding to collagen. Fur-
thermore, binding of vWF to collagen types I and III is
thought to play an important role in the growth of
thrombi on ruptured atherosclerotic lesions, which are
responsible of the occlusion of coronary arteries leading
to myocardial infarction.
We present the crystal structure of the A3 domain of
vWF (residues 920–1111), which is primarily responsi-
ble for binding to types I and III collagen. The compact
molecule exhibits a so-called dinucleotide binding fold
similar to the integrin I domains. The conserved location
of the active and ligand-binding sites in proteins with this
fold, allows us to identify a putative site of collagen inter-
action in vWF A3. This region encompasses a potential
metal ion-binding site, with the conserved motif DXSXS.
The observed conformation of the metal-binding region
of A3 is distinct from that of the homologous I-type
domains of integrins CR3 and LFA-1, and is incompati-
ble with ion binding. In contrast to CR3 and LFA-1, no
functional role for metal ion binding in activation of
ligand binding has been observed for vWF. Overall, the
putative collagen interaction surface is primarily smooth
and negatively charged and is distinctly different from
protein domains that bind (partly) unwound collagen-
triple helices. The available data suggest that tight asso-
ciation is achieved through a large number of low affinity
interactions between multiple negatively charged inter-
action surfaces of A3 domains present in multimeric
vWF with positively charged binding sites along intact
collagen triple helices. Thus, our crystal structure pro-
vides a structural basis for the understanding of the adhe-
sion process of vWF to exposed collagen types I and III
in haemostasis and a starting point for site-directed
mutagenesis to test the importance of individual residues
in vWF-A3 for collagen binding. 
Materials and methods
Cloning and expression
A DNA fragment encoding residues 920–1111 of human vWF was
amplified by PCR from a plasmid containing full length vWF cDNA. The
PCR fragment was cloned into the NdeI and BamHI sites of expression
vector pET15b (Novagen) [46], which results in a fusion to a N-terminal
Histidine tag with a thrombin cleavage site. Absence of mutations intro-
duced by the PCR reaction was confirmed by nucleotide sequencing.
For protein expression, the pET15b-A3 plasmid was transformed into E.
coli strain B834(DE3), which is a methionine auxotroph [47]. Bacteria
were cultured in rich medium in a 10 liter fermenter. Care was taken not
to allow the overnight starter culture to reach the stationary growth
phase, because this lead to loss of plasmid. Protein expression was
induced at a cell density of OD 1.5 by addition of isopropyl-b -D-thio-
galactopyranoside (IPTG) to a final concentration of 0.5 mM. Final ODs
of 6.5 were reached. The bacteria were collected by centrifugation and
stored at –20° C until protein isolation. For production of selenomethion-
ine (Se-Met) A3, bacteria were cultured in new minimal medium (NMM)
as described by Budisa et al. [48]. Firstly, bacteria were grown in
200 ml NMM supplemented with 0.3 mM L-methionine. After reaching
an OD of 0.5, the bacteria were pelleted by centrifugation, resuspended
in NMM without methionine and added to a 5 liter fermenter filled with
NMM supplemented with 0.3 mM L-Se-Met. Bacteria grew very poorly in
the presence of Se-Met. After 16 hours IPTG was added at OD 0.6.
The culture was stopped 4 hours after induction at OD 0.7.
Refolding and purification
The frozen bacterial pellet was thawed and resuspended in ice-cold
lysis buffer (50 mM Tris/HCl pH 8.6, 150 mM NaCl) at about 0.3 g/ml.
Lysis was achieved by a 15 min incubation with 200 m g/ml lysozyme
followed by sonication. After centrifugation at 14,000 g for 20 min the
pellet was washed in lysis buffer containing 0.05% (w/v) desoxycholine
and 1% (v/v) Triton-X100 and again centrifugated. The washed pellet
contained insoluble A3 protein. 
The protein was refolded essentially as described by Cruz et al. [22].
The washed pellet was dissolved in 8 M urea, 50 mM Tris/HCl pH 8.8,
and dialysed against 25 mM Tris/HCl pH 8.2 at 4 ° C. After overnight
dialysis, particulate material was removed by centrifugation at 14,000
g followed by filtration through a 0.22 m m filter. The solution was
loaded on Ni2+/NTA Sepharose (Quiagen) and washed extensively
with buffer containing 25 mM Tris/HCl pH 8.2, 300 mM NaCl and
25 mM imidazol. The protein was eluted with a linear gradient of
0–0.5 M imidazol in wash buffer. Protein containing fractions were
pooled and dialysed overnight against 25 mM Tris/HCl pH 8.2. After
dialysis a small amount of precipitated protein was removed by filtra-
tion through a 0.22 m m filter.
The histidine tag was removed by thrombin digestion. After adding final
concentrations of 50 mM NaCl and 2 mM CaCl2, the protein was
digested for 2 hours at room temperature with 1:1000 (w/w) thrombin:
A3 (purified human thrombin was a kind gift from Walter Kisiel, Univer-
sity of New Mexico, Albuquerque, NM, USA). Digestion was stopped
with 0.5 mM phenylmethylsulfonyl fluoride (PMSF). In order to remove
any uncleaved protein, the digestion mixture was filtered through a
Ni2+/NTA Sepharose column. The flow through was diluted with an
equal volume of 25 mM Tris/HCl pH 8.2 and loaded on a Pharmacia Q-
Sepharose column. The column was developed with a linear gradient of
0–0.3 M NaCl in 25 mM Tris/HCl pH 8.2. Peak fractions were pooled,
dialysed against 10 mM Tris/HCl pH 8.2 and concentrated by ultra-filtra-
tion to a final concentration of about 10 mg/ml.
Se-Met A3 was purified using the same procedure as used for the
native protein with the exception that the bacterial lysate was loaded
directly on a Ni2+/NTA Sepharose column, because the protein was
predominantly in the soluble fraction of the bacterial lysate.
Crystallization
Crystals were grown using the hanging drop vapour diffusion method
with reservoir solutions containing 200 mM sodium acetate, 0.1 M
Tris/HCl buffered at pH 8.5 and varying amounts of PEG 3000. Initially,
intergrown crystals were obtained using a reservoir solution containing
30% (w/v) PEG 3000. Crystal quality was improved markedly by using
a micro-seeding procedure. A crystal was fragmented with a glass fiber
and the fragments were diluted 102, 103 and 104 fold in reservoir solu-
tion containing 30% PEG. Of the diluted seed solutions, 0.4–1.0 m l
was added to a drop consisting of 1 m l protein solution and 2 m l reser-
voir solution containing 24% PEG. The drop was equilibrated against
reservoir solution containing 24–26% PEG. Crystals grew to a final
size of up to 0.6 mm · 0.2 mm · 0.2 mm, but these larger crystals could
not be handled without breaking. Only smaller crystals with dimensions
of about 0.30 mm · 0.15 mm · 0.15 mm were suitable for X-ray diffrac-
tion data collection.
Se-Met A3 was crystallized using the same seeding procedure and
microseeds prepared from a crystal of the native protein. Nevertheless,
the native and the Se-Met A3 crystals have a different space group.
The native protein crystallizes in space group P21 with unit cell dimen-
sions a = 35.2 Å, b = 98.5 Å, c = 44.6 Å and b = 90.6° , whereas the
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Se-Met A3 crystals have the space group P212121 with unit cell dimen-
sions a = 35.1 Å, b = 44.4 Å, c = 98.1 Å.
Data collection and processing
Diffraction data were collected from crystals soaked for 1–2 minutes in
reservoir solution containing 30% (w/v) PEG and 15% (v/v) glycerol.
Crystals were frozen in a gaseous nitrogen stream of 100 K from an
Oxford cryo-system. Native data were collected on beam line X11 of
the EMBL outstation (DESY, Hamburg) using a big MAR Research
image plate. To cover the whole dynamic range of diffraction intensities
between 20 and 1.1 Å resolution, three data sets were collected with
varying exposure times and crystal to image plate distances. For the
low resolution data set, tin-foil was inserted into the X-ray beam to
attenuate its intensity. MAD data were collected on beam line X31 of
the EMBL outstation, using a small MAR Research image plate detec-
tor. The X-ray absorption edge of Se was determined by measuring an
X-ray fluorescence spectrum. A single P212121 Se-Met crystal was
used for collection of 2.3 Å data at three wavelengths: at the maximum
of the Se absorption edge (“edge” data, l = 0.9790 Å), at the inflection
point of the Se absorption edge (“inflection” data, l = 0.9792 Å) and
far from the Se absorption edge on the high energy side (“remote”
data, l = 0.90 Å). No particular effort was taken to orient the crystal in
the X-ray beam. The three data sets were collected one after the other
using 1° oscillations. All data were reduced using the program DENZO
and scaled with SCALEPACK [49] (Table 1).
Phase determination
Programs in the CCP4 suite [50] were used for heavy-atom phase cal-
culation and refinement (MLPHARE) and for map calculation. The posi-
tions of four of the five Se atoms present in the construct were
determined from an isomorphous difference Patterson map calculated
from the remote and inflection point data sets. Phase calculation by
MLPHARE was dominated by dispersive differences between the
remote and the inflection data sets (Table 2). Low phasing power of
the anomalous signal in the edge data set is possibly caused by prob-
lems experienced with wavelength stabilization during collection of this
particular data set. These problems had been solved during collection
of the inflection dataset. The electron density map calculated from
MAD phases with a figure of merit of 0.65 could easily be interpreted
without using density modification techniques. 
Model building and refinement
Model building was carried out with O [51]. An initial model was built in
an electron-density map calculated with structure factors from the remote
data set and MAD phases from MLPHARE. Three cycles of model build-
ing alternated with simulated annealing refinement against remote Fs and
MAD phases using X-PLOR [52] produced a partly refined model with an
R factor of 26.8% (Rfree = 37.1%) for data between 2.3–8.0 Å resolution.
The cell dimensions of the orthorhombic unit cell of the Se-Met A3 crys-
tals are close to those of the monoclinic cell of the native A3 crystals and
the molecular packing in both crystal forms is very similar. Two copies of
the partially refined model in P212121 were transformed to the P21 cell of
the native crystal form and their position and orientation was optimized by
rigid-body refinement. Subsequent refinement was carried out using the
native dataset up to a resolution of 1.8 Å. No restraints were used to
impose non-crystallographic symmetry. The structure was refined to an R
factor of 17.4% and a Rfree of 24.0% for data between 1.8 and 8.0 Å res-
olution. The model includes two A3 molecules comprising residues
925–1107 and residues 922–1110, respectively, as well as 350 water
molecules and it has good geometry (Table 3). 
Accession numbers 
Coordinates for the vWF-A3 domain have been deposited with the
Brookhaven Protein Data Bank (accession code 1atz).
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